Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Peer Reviewed
See detailPrevention of neonatal group B streptococcal disease in Belgium: hospital policy, obstetricians' practice and laboratory processing
MELIN, Pierrette ULg; Schmitz, Myriam; Heinrichs, I. et al

in American Society of Microbiology (Ed.) Program and Abstracts of the 40th Intersciences Conference on Antimicrobial Agents and Chemotherapy (2000, September)

Detailed reference viewed: 20 (5 ULg)
Full Text
Peer Reviewed
See detailPrevention of Osteoporosis with Nasal Salmon Calcitonin: Effect of Anti-Salmon Calcitonin Antibody Formation
Reginster, Jean-Yves ULg; Gaspar, S; Deroisy, Rita ULg et al

in Osteoporosis International : A Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis & the National Osteoporosis Foundation of the USA (1993), 3

The amino acid sequence of salmon calcitonin (SCT) differs considerably from that of the human hormone and specific antibodies (Ab) develop in a significant proportion of patients after parenteral or ... [more ▼]

The amino acid sequence of salmon calcitonin (SCT) differs considerably from that of the human hormone and specific antibodies (Ab) develop in a significant proportion of patients after parenteral or nasal administration of SCT. Controversy remains regarding the functional importance of these Ab. We report on the development of specific anti-SCT Ab in a population of postmenopausal women receiving nasal SCT for prevention of postmenopausal bone loss, and compare the effects of nasal SCT in women with or without Ab. Thirty-nine per cent of women developed Ab after 6 months of treatment with SCT, 52% after 12 months, and 61% after 18 and 24 months. After 24 months the AB titre was 3.47-17.7 x 10(-9) M/l (mean +/- SD: 13.3 +/- 3.1 x 10(-9) M/l). No significant differences appeared between the changes in lumbar bone mineral density (BMD) measured in the whole population (n = 44) (mean +/- SD: +1.06 +/- 3.9%), the patients without Ab (n = 17) (+0.05 +/- 3.7%) or in those with Ab (n = 27) (+1.7 +/- 4.6%). During the same period, a control population randomly assigned to a 500 mg/day calcium intake showed a significant loss of lumbar BMD (-4.57 +/- 4.9%) (p < 0.01). In conclusion, in healthy postmenopausal women nasal SCT seems to maintain the same preventive effect against bone loss whether or not Ab are present. [less ▲]

Detailed reference viewed: 11 (3 ULg)
See detailPrevention of perinatal GBS Diseases: Recommendations in European Countries, Proposal for Belgium
MELIN, Pierrette ULg

Scientific conference (2001, November 17)

Detailed reference viewed: 9 (0 ULg)
See detailPrevention of perinatal GBS infections: update and guidelines
MELIN, Pierrette ULg

Conference (2004, December 17)

Detailed reference viewed: 13 (0 ULg)
Full Text
See detailPrevention of perinatal group B streptococcak diseases: update and guidelines
MELIN, Pierrette ULg

in Ducoffre, Geneviève (Ed.) Program and Abstracts book of 2005 Symposium of ISP (2005, November 17)

Face à l’importance et à la gravité des infections périnatales à streptocoques du groupe B (GBS), depuis dix ans, différentes approches préventives ont été proposées. Le point commun est l’administration ... [more ▼]

Face à l’importance et à la gravité des infections périnatales à streptocoques du groupe B (GBS), depuis dix ans, différentes approches préventives ont été proposées. Le point commun est l’administration intraveineuse d’antibiotiques pendant le travail et l’accouchement aux patientes identifiées « à risque » soit par un dépistage de colonisation maternelle pendant la grossesse, soit par la présence de facteurs de risque définis. En 2002, après quelques années d’implémentation et d’adoption des recommandations éditées par le CDC (Centers for Diseases Control and Prevention, Atlanta, USA) en 1996, différentes études ont évalué l’efficacité des alternatives et ont démontré pour différentes raisons, la supériorité du dépistage pendant la grossesse pour l’identification des mères « à risque ». C’est pourquoi, en août 2002, le CDC publiait une version révisée des recommandations en proposant un dépistage universel, c'est-àdire de TOUTES les femmes enceintes. Parallèlement d’autres pays, notamment la France et la Belgique, évaluaient aussi l’efficacité et la faisabilité de différentes stratégies plus ou moins proches de celles du CDC. Depuis juillet 2003, les recommandations belges « Prevention of Perinatal Group B streptococcal Infections. Guidelines from the Belgium Health Council . (SHC. 721) » sont disponibles sur le site du CSH : (http://www.health.fgov.be/CSH_HGR/Francais/Brochures/GBS_2003.pdf et http://www.health.fgov.be/CSH_HGR/Nederlands/Brochures/GBS_2003.pdf). Ces recommandations sont très proches de celles du CDC moyennant quelques adaptations techniques et de prises en charge des nouveau-nés et, qui devraient en améliorer l’efficacité. Ces recommandations belges seront présentées et discutées. L’efficacité optimale attendue de ces recommandations est une réduction de 75% des cas d’infection néonatale précoce confirmés par culture. Pour atteindre cet objectif, la communication et une coordination multidisciplinaires sont indispensables entre le service de gynécologie-obstétrique, le laboratoire, le bloc d’accouchement et le service de néonatologie. [less ▲]

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailPrevention of Perinatal Group B Streptococcal Diseases: Belgian Guidelines
Melin, Pierrette ULg

in Round Table Series (2007), 85

Detailed reference viewed: 27 (3 ULg)
Full Text
See detailPrevention of Perinatal Group B Streptococcal Infections - Guidelines from the Belgian Health Council, 2003 (SHC.7721)
Working party of experts, Superior Health Concil; Dubois, J. J.; MELIN, Pierrette ULg et al

Book published by Superior Health Council (2003)

Detailed reference viewed: 16 (2 ULg)
Full Text
Peer Reviewed
See detailPrevention of postmenopausal bone loss by administration of boron
Biquet, I; COLLETTE, Julien ULg; Dauphin, JF et al

in Osteoporosis International (1996), 6(S1), 249

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailPrevention of Postmenopausal Bone Loss by Rectal Calcitonin
Reginster, Jean-Yves ULg; Jupsin, Isabelle ULg; Deroisy, Rita ULg et al

in Calcified Tissue International (1995), 56

A group (150) of healthy women, who had been menopausal for less than 5 years and who had never received any form of treatment to prevent bone loss were entered into a randomized, controlled study ... [more ▼]

A group (150) of healthy women, who had been menopausal for less than 5 years and who had never received any form of treatment to prevent bone loss were entered into a randomized, controlled study comprising three arms. They were randomly allocated to the double-blind administration of five suppositories per week containing either 100 IU of salmon calcitonin or a placebo, or to a group receiving a suppository containing 200 IU of salmon calcitonin three times per week. All women received 500 mg/day of calcium supplementation. After 12 months, bone mineral density (BMD) of the spine, measured by dual energy X-ray absorptiometry, decreased significantly (P < 0.01) in the placebo group by 3.1% (SD: 3.6%) but did not change in the two calcitonin groups [+1.3% (3.5%) with 100 IU/day and +2.3% (4.0%) with 200 IU 3/week]. The differences in response between the placebo group and the two calcitonin groups were significant (P < 0.05), but the difference between the two regimens of calcitonin administration was not. No differences appeared among the three groups for the response at the level of the hip. Evolution of biochemical markers reflecting bone turnover did not differ significantly among groups. Nearly 40% of the women withdrew prematurely because of local (rectal or intestinal) intolerance to repetitive suppositories, with a nonsignificantly different frequency in the placebo or calcitonin groups. We conclude that rectal calcitonin might be an interesting preventive approach against trabecular postmenopausal bone loss but that long-term acceptability of suppositories should be evaluated in view of each patient's sensibility or cultural background. [less ▲]

Detailed reference viewed: 6 (2 ULg)
Peer Reviewed
See detailPrevention of postmenopausal bone loss by tiludronate
Reginster, Jean-Yves ULg; Lecart, MP; DEROISY, Rita ULg et al

in Menopause Digest (1990), 4

Detailed reference viewed: 13 (2 ULg)
Peer Reviewed
See detailPrevention of postmenopausal bone loss by tiludronate
Reginster, Jean-Yves ULg; DEROISY, Rita ULg; Lecart, MP et al

in Japanese Journal of Bone and Metabolism (1990), 8

Detailed reference viewed: 11 (3 ULg)
Full Text
Peer Reviewed
See detailPrevention of Postmenopausal Bone Loss by Tiludronate
Reginster, Jean-Yves ULg; Lecart, M. P.; Deroisy, Rita ULg et al

in Lancet (1989), 2(8678-8679, Dec 23-30), 1469-71

76 healthy women, who had been menopausal for less than 96 months and who had never received any form of treatment to prevent bone loss, were entered into a randomised double-blind study. For the first 6 ... [more ▼]

76 healthy women, who had been menopausal for less than 96 months and who had never received any form of treatment to prevent bone loss, were entered into a randomised double-blind study. For the first 6 months, half the patients received tiludronate 100 mg daily, while the others received placebo. During the second 6 months, all patients received placebo. Bone mineral density of the lumbar spine decreased significantly by 2.1% (SE 0.8%) in the placebo group and did not significantly change in the tiludronate group (+1.33 [0.8]%). The difference in response between the groups was significant, as were the differences between values for corrected urinary hydroxyproline and calcium. Treatment with tiludronate was not followed by increased secretion of parathyroid hormone. A 6 month course of oral tiludronate may counteract postmenopausal bone loss for at least a year by decreasing bone resorption. [less ▲]

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailPrevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities
Reginster, Jean-Yves ULg

in Journal of Internal Medicine (2004), 255(6), 615-628

Postmenopausal osteoporosis (PMO) is a common disease that will become more prevalent in the future, with costly implications for public health. Prevention of the disease and its consequences, namely ... [more ▼]

Postmenopausal osteoporosis (PMO) is a common disease that will become more prevalent in the future, with costly implications for public health. Prevention of the disease and its consequences, namely fractures, is therefore, important for both the individual and society. This review discusses: the goals of PMO prevention; the identification of women at risk, including the use of bone mineral density and bone turnover markers; the relevance in the prevention setting of various current guidelines for PMO management; recent data on therapeutic options for the treatment and prevention of PMO, in particular bisphosphonates, hormone replacement therapy and several other new pharmacological agents. It concludes that it is crucial for PMO prevention to start before disease onset and that, in the light of recent evidence, the existing guidelines need updating if they are to continue to be relevant. [less ▲]

Detailed reference viewed: 16 (0 ULg)
See detailPrevention of Reflective Cracking in Pavements (Chapter 4)
Courard, Luc ULg; Vanelstraete, A.; de Bondt, A. et al

in • Characterization of overlay systems (1997)

Detailed reference viewed: 24 (3 ULg)
Full Text
See detailPrevention of spectators’ violence and safety in football stadiums
Comeron, Manuel ULg

Scientific conference (2007, May 30)

Detailed reference viewed: 39 (9 ULg)
Full Text
Peer Reviewed
See detailThe prevention of spontaneous apoptosis of follicular lymphoma B cells by a follicular dendritic cell line: involvement of caspase-3, caspase-8 and c-FLIP.
Goval, Jean-Jacques; Thielen, Caroline ULg; Bourguignon, Caroline et al

in Haematologica (2008), 93(8), 1169-77

BACKGROUND: Follicular lymphoma, the neoplastic counterpart of germinal center B cells, typically recapitulates a follicular architecture. Several observations point to the crucial role of the cellular ... [more ▼]

BACKGROUND: Follicular lymphoma, the neoplastic counterpart of germinal center B cells, typically recapitulates a follicular architecture. Several observations point to the crucial role of the cellular microenvironment in the development and/or progression of follicular lymphoma cells in vivo. The aim of our study was to characterize the spontaneous apoptosis of follicular lymphoma cells in vitro, and the modulation of this apoptosis by follicular dendritic cells. DESIGN AND METHODS: We used a cell line derived from follicular dendritic cells to model the functional interactions of these cells and lymphoma cells in co-culture. Follicular lymphoma cells were isolated from tissue biopsies. Apoptosis was quantified by flow cytometry and apoptotic pathways were investigated by western blotting. RESULTS: The spontaneous apoptosis of follicular lymphoma cells in vitro involves the activation of caspases-3 and -8 but not of caspase-9, occurs despite persistent high levels of BCL-2 and MCL-1, and is associated with down-regulation of c-FLIP(L). Spontaneous apoptosis of follicular lymphoma cells is partially prevented by co-culture with the follicular dendritic cells, which prevents activation of caspase-8, caspase-3 and induces an upregulation of c-FLIP(L). Using neutralizing antibodies, we demonstrated that interactions involving CD54 (ICAM-1), CD106 (VCAM-1) and CD40 are implicated in this biological process. CONCLUSIONS: Follicular dendritic cells constitute a useful tool to study the functional interactions between follicular lymphoma cells and follicular dendritic cells in vitro. Understanding the molecular mechanisms involved in these protective interactions may lead to the identification of therapeutic agents that might suppress the survival and growth of follicular lymphoma cells. [less ▲]

Detailed reference viewed: 63 (6 ULg)
Full Text
Peer Reviewed
See detailPrevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
Scheen, André ULg

in Drugs (2004), 64(22), 2537-65

Type 2 diabetes mellitus is becoming a major health problem associated with excess morbidity and mortality. As the prevalence of type 2 diabetes is rapidly increasing, prevention of the disease should be ... [more ▼]

Type 2 diabetes mellitus is becoming a major health problem associated with excess morbidity and mortality. As the prevalence of type 2 diabetes is rapidly increasing, prevention of the disease should be considered as a key objective in the near future. Besides lifestyle changes, various pharmacological treatments have proven their efficacy in placebo-controlled clinical trials, including antidiabetic drugs such as metformin, acarbose and troglitazone, or antiobesity agents such as orlistat. Arterial hypertension, a clinical entity in which insulin resistance is common, is strongly associated with type 2 diabetes and may precede the disease by several years. While antihypertensive agents such as diuretics or beta-adrenoceptor antagonists may worsen insulin resistance and impair glucose tolerance, newer antihypertensive agents exert neutral or even slightly positive metabolic effects. Numerous clinical trials have investigated the effects of ACE inhibitors or angiotensin II receptor antagonists (ARAs) on insulin sensitivity in hypertensive patients, with or without diabetes, with no consistent results. Almost half of the studies with ACE inhibitors in hypertensive nondiabetic individuals demonstrated a slight but significant increase in insulin sensitivity as assessed by insulin-stimulated glucose disposal during a euglycaemic hyperinsulinaemic clamp, while the other half failed to reveal any significant change. The effects of ARAs on insulin sensitivity are neutral in most studies. Mechanisms of improvement of glucose tolerance and insulin sensitivity through the inhibition of the renin-angiotensin system (RAS) are complex. They may include improvement of blood flow and microcirculation in skeletal muscles and, thereby, enhancement of insulin and glucose delivery to the insulin-sensitive tissues, facilitating insulin signalling at the cellular level and improvement of insulin secretion by the beta cells. Six recent large-scale clinical studies reported a remarkably consistent reduction in the incidence of type 2 diabetes in hypertensive patients treated with either ACE inhibitors or ARAs for 3-6 years, compared with a thiazide diuretic, beta-adrenoceptor antagonist, the calcium channel antagonist amlodipine or even placebo. The relative risk reduction averaged 14% (p = 0.034) in the CAPPP (Captopril Prevention Project) with captopril compared with a thiazide or beta1-adrenoceptor antagonist, 34% (p < 0.001) in the HOPE (Heart Outcomes Prevention Evaluation) study with ramipril compared with placebo, 30% (p < 0.001) in the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) with lisinopril compared with chlortalidone, 25% (p < 0.001) in the LIFE (Losartan Intervention For Endpoint reduction in hypertension study) with losartan compared with atenolol, and 25% (p = 0.09) in the SCOPE (Study on Cognition and Prognosis in the Elderly) with candesartan cilexetil compared with placebo, and 23% (p < 0.0001) in the VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial with valsartan compared with amlodipine. All these studies considered the development of diabetes as a secondary endpoint, except the HOPE trial where it was a post hoc analysis. These encouraging observations led to the initiation of two large, prospective, placebo-controlled randomised clinical trials whose primary outcome is the prevention of type 2 diabetes: the DREAM (Diabetes REduction Approaches with ramipril and rosiglitazone Medications) trial with the ACE inhibitor ramipril and the NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research) trial with the ARA valsartan. Finally, ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) will also investigate as a secondary endpoint whether it is possible to prevent the development of type 2 diabetes by blocking the RAS with either an ACE inhibitor or an ARA or a combination of both. Thus, the recent consistent observations of a 14-34% reduction of the development of diabetes in hypertensive patients receiving ACE inhibitors or ARAs are exciting. From a theoretical point of view, they emphasise that there are many aspects of the pathogenesis, prevention and treatment of type 2 diabetes that still need to be uncovered. From a practical point of view, they may offer a new strategy to reduce the ongoing epidemic and burden of type 2 diabetes. [less ▲]

Detailed reference viewed: 43 (1 ULg)
Full Text
See detailPrevention of violence in football stadiums in Europe
Comeron, Manuel ULg; Kellens, Georges ULg; Vanbellingen, Pierre

Book published by asbl Fan coaching-Eurofan (2002)

Exchanges about European practices of hooliganism prevention and sharing of scientific studies about this phenomenon in Europe.

Detailed reference viewed: 56 (6 ULg)
Full Text
See detailThe prevention of violence in sport
Comeron, Manuel ULg

Book published by Coucil of Europe Publishing (2003)

The beginning of this century has seen a shift in the type of violence associated with sports events, in particular football. Once contained by football grounds and generally one-off and spontaneous in ... [more ▼]

The beginning of this century has seen a shift in the type of violence associated with sports events, in particular football. Once contained by football grounds and generally one-off and spontaneous in nature, sports violence has moved to urban areas and city centres. Contemporary society is now confronted with sports violence which is often premeditated, and commonly involves hard-core supporters who seek systematic and organised confrontation at local, national and international matches and tournaments. As hooliganism becomes international, generating similar problems in Europe and throughout the world, a common and concerted preventive response at international level is needed. The prevention of violence in sport proposes actions and structures based on experiments in progress which have already shown some degree of effectiveness. These initiatives open up a range of solutions for developing integrated preventive activities of a high standard that can be adapted to local needs. [less ▲]

Detailed reference viewed: 25 (1 ULg)